Please assess the completion status of the following clinical trial:

Trial Title: Pre-operative Decitabine in Colon Cancer: a Proof of Principle Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
In- and exclusion criteria first part:~In order to participate in the first part of the study, five extra fresh biopsies to determine tumor methylation status, a subject must meet all of the following criteria:~Inclusion criteria:~1. Biopsy proven colon cancer or high suspicion of colon cancer on a previous endoscopy.~2. Planned endoscopy.~3. Age ≥ 18yr.~4. ECOG/ WHO performance 0-2.~5. Written informed consent.~Exclusion criteria:~1. Any psychological, familial, sociological or geographical condition potentially hampering adequate informed consent or compliance with the study protocol.~In- and exclusion criteria second part:~In order to participate in the second part of the study - treatment with decitabine - a subject must meet all of the following criteria:~Inclusion criteriä:~1. Patients with biopsy proven colon cancer who will undergo primary tumor resection.~2. Age ≥ 18yr.~3. ECOG/ WHO performance 0-2.~4. Adequate bone marrow function (ANC\>1500/mm3, hemoglobin\>9g/dL (which may be obtained by transfusions), platelets\>100,000)~5. Adequate hepatic function (AST and ALT \<2.5x upper limit of normal (ULN)).~6. Adequate renal function (Serum creatinine ≤1.5 x ULN or calculated creatinine of \>50ml/min)~7. Women of child-bearing age must be willing to use adequate contraception and have negative serum or urine pregnancy test within 3 days prior to registration.~8. Written informed consent.~Exclusion criteria:~1. Known hypersensitivity to decitabine or its additives.~2. Surgery not planned according to time frame of the study,~3. Other systemic or local treatment of the primary tumor in the waiting time until surgery.~4. Administration of any experimental drug within 60 days prior to the first dose of decitabine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Decitabine treatment (Type: EXPERIMENTAL): Treatment with decitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).